price, page-11

Could also be due in part from Abbvie's HCV results announced yesterday.

http://www.fiercebiotech.com/press-releases/abbvie-present-late-breaker-pearl-iii-study-patients-chronic-hepatitis-c-21-0

Still - if TT-034 works it'd supplant this treatment,
esp with it's crappy side effects being at quite a high rate, and still the issue of non compliance outside of a trial setting.
I'm still backing the new paradigm because if it cures HCV it's every chance to give HBV and HIV a good belting too.

"
The most commonly reported adverse events (>10 percent for either arm) were headache, fatigue, pruritus, nausea and asthenia, with pruritus and nausea occurring at a statistically higher rate in the treatment arm with RBV compared to the arm without RBV. Anemia occurred more commonly among patients in the RBV-containing arm with clinically significant anemia requiring RBV dose reductions occurring in 9 percent of these patients.
"